All News

AUA expressed 'strong opposition' to the health care reform legislation amendment eliminating the self-referral exemption for in-office ancillary services such as CT scans on the same day The Washington Post ran an article with the headline 'Doctors Reap Benefits By Doing Own Tests.'

A look at urology drugs and devices in the pipeline.

An overview of new agents and device-assisted therapies being investigated to improve outcomes for patients with superficial bladder cancer.

This article reviews current developments in cellular scaffods, the process of cell seeding, and the importance of a favorable in vitro environment for regeneration.

For the first time, 17 of Advanstar Communications' Life Sciences publications and its web portal, ModernMedicine.com, are collaborating in a coordinated, interdisciplinary initiative to address a major public health issue: cardiometabolic disorders and weight.

The FDA has announced that boxed warnings are now included on labels of four botulinum toxin drug products, revising a previous safety alert on the products. The products also now include medication guides for patients, as mandated by FDA in April.

President Barack Obama's remarks regarding care given by U.S. surgeons has prompted a response from the American College of Surgeons, which says it is "deeply disturbed" over comments that are inaccurate.

Elevated anxiety and distress levels don?t appear to be present in men with early stages of prostate cancer who wait to pursue radical treatment and instead opt for expectant management, a recently published study has found.

Advanced prostate cancer patients who are treated with oral sodium clodronate appear to have improved survival rates, according to results of a British study.

The FDA Advisory Committee for Reproductive Health Drugs (ACRHD) has recommended approval of denosumab (Prolia) for prevention and treatment of bone loss in certain prostate cancer patients.

Financial solvency obstacles and implementing an electronic health record are the top challenges facing medical practices and their respective practice managers, according to a survey by the Medical Group Management Association (MGMA).

James L. Mohler, MD, has been promoted to senior vice president for translational research at Roswell Park Cancer Institute (RPCI) in Buffalo, NY.

Endoscopic technology developer Karl Storz Endoscopy-America, Inc. has established a reseller agreement with Rivulet Communications, which produces high-definition medical video technology for hospital IP networks.

Internationally recognized kidney disease expert Gregory G. Germino, MD, has been named deputy director of the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

A second and final phase III, multicenter, double-blind, placebo-controlled study of PSD502 for premature ejaculation treatment has met all endpoints, according to Sciele Pharma and Plethora Solutions Holdings. Those endpoints include intra-vaginal ejaculation latency time and the index of premature ejaculation (IPE; ejaculatory control, sexual satisfaction, and distress domains).

Researchers at the Stanford University School of Medicine, Stanford, CA have identified the first human bladder cancer stem cell and have explained its role in evading the body?s natural defenses.

Genentech, Inc. has earned FDA approval for bevacizumab (Avastin) plus interferon-alfa for treatment of metastatic renal cell carcinoma. Bevacizumab blocks the vascular endothelial growth factor (VEGF) protein responsible for tumor growth.

The better the relationship is between men and their health care provider, the greater their chance of receiving prostate cancer screening and the less likely they are to be diagnosed with advanced prostate cancer, regardless of their race, researchers from the University of North Carolina, Chapel Hill, and Roswell Park Cancer Institute, Buffalo, NY, reported in Cancer online.

In the 15 years following a radical prostatectomy, there is only a 12% mortality rate directly connected to prostate cancer, regardless of the cancer?s aggressiveness, according to a multicenter study appearing in the Journal of Clinical Oncology online. Comparatively, there was a 38% rate of non-cancer-related death in this same group of patients.

Incidentally detected small renal masses (SRMs) are not always cancer, and even those that are biopsy-proven renal cell carcinoma tend to grow slowly initially and have a low risk of metastasis, according to analyses of data.

Among surgeons contemplating performing a minimally invasive partial nephrectomy, the choice of procedure boils down to the approach that provides the highest level of comfort for the surgeon.

It's not clear yet whether transvaginal mesh offers superior anatomic or symptomatic outcomes compared to traditional apical suspension repairs.

In patients with primary T1G3 bladder cancer who undergo initial treatment with endovesical bacillus Calmette-Guerin (BCG [TheraCys, TICE BCG]), development of high-grade disease recurrence after 3 months is a prognostic factor for progression.

New products from Uvision, Caldera Medical, Serono, Lumenis, American Medical Systems, and more.

While some urology practices are adding physician extenders, others are having as much difficulty finding them as finding urologists.

Urologists around the country lament the difficulty in finding and keeping good employees, and even gripe about the deteriorating performance and attitudes found in some of the more demanding positions. My advice: They're your employees, so it's time to take ownership of the problem.

Combination of an immunofluorescence test and cytology may improve quality of bladder cancer diagnostics.

In an earlier article, we examined the reasons why an early EMR adopter might need to migrate to an entirely new clinical information system and some of the important issues that need to be addressed in managing that migration. In this article, we show how one practice overcame these challenges.

The question is no longer if health care reform will occur, but when and what it will look like.